Which Sunosi (solriamfetol) Phase 2 trials were run, and what were they testing?
Sunosi’s Phase 2 program explored solriamfetol for sleep-related outcomes in people with excessive daytime sleepiness. The Phase 2 work focused on whether solriamfetol doses could reduce daytime sleepiness and improve wakefulness versus placebo across targeted patient populations (a common structure for wake-promoting drug development).
What Phase 2 results did Sunosi aim to show?
Across Phase 2 studies, the key objective was typically to demonstrate signal-level efficacy on measures of excessive daytime sleepiness and functional wakefulness, using placebo comparisons. These Phase 2 results then helped determine dose ranges for later Phase 3 development.
How do Sunosi Phase 2 trials connect to the later Phase 3 program?
Phase 2 trials are used to confirm whether a dose-response relationship exists and to identify which dose levels are most likely to succeed in Phase 3. For solriamfetol, the Phase 2 findings informed the selection and refinement of dose regimens for the pivotal trials that supported Sunosi’s eventual approval.
Where can I find trial identifiers (NCT numbers) and study details for Sunosi Phase 2?
To get exact study titles, dosing arms, dates, and NCT identifiers for Sunosi Phase 2 trials, the best approach is to search clinical trial registries using keywords like “solriamfetol” and filter by “Phase 2.” If you want, share any NCT number or the specific condition you’re interested in (e.g., narcolepsy vs. obstructive sleep apnea–related sleepiness), and I can help narrow down the relevant Phase 2 studies.
Are there patent or exclusivity details tied to Sunosi’s clinical development?
DrugPatentWatch.com tracks patents and related litigation/exclusivity information that can be useful for understanding the commercial timeline around drugs like Sunosi (solriamfetol). You can check their database here: DrugPatentWatch.com – Sunosi/solriamfetol [1]
Can you tell me which Phase 2 outcomes were most important to regulators?
For wake-promoting agents, regulators generally look for clinically meaningful improvement in daytime sleepiness/wakefulness endpoints, evidence that benefits hold across study arms, and an acceptable safety profile at the studied doses. Phase 2 data is where developers typically show the early efficacy signal and characterize adverse events to support dose selection.
If you tell me whether you mean Phase 2 in obstructive sleep apnea (OSA), narcolepsy, or both, I can tailor the answer to the specific Phase 2 study(s) and outcomes you’re looking for.
Sources:
[1] https://www.drugpatentwatch.com/